Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

J Clin Med · 2024 · PMC11354391 · PMID 39200727

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Importantly, combined therapy with Lu-177 PSMA-617 RLT and ARPIs showed a trend towards improved OS, with a median of 20.3 months versus 15.9 months for those receiving Lu-177 PSMA-617 RLT alone (HR 0.58; 95% CI, 0.33–1.02; p = 0.06) ( Figure 4 ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

12.3 months, respectively), the OS differences did not reach statistical significance in either study [ 15 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.